Patent filing follows acceptance into the NVIDIA Connect Program Proprietary software targets weather forecast-driven revenue optimization, reduced penalty risk, and improved market performance for utility-scale solar assets TEL AVIV, Israel, Jan. 20, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF” or the “Company”) (formerly “PainReform”) today announced that it has filed a patent application covering proprietary methods for solar plant–level micro-climate modeling designed to signifi ...

Core Viewpoint - PainReform Ltd. has changed its name to PRF Technologies Ltd. to better reflect its expanding portfolio, which now includes specialty pharmaceuticals and AI-driven renewable energy analytics [1][2]. Company Developments - The company is advancing its non-opioid postoperative pain therapy, PRF-110, and developing new products like OcuRing-K, a dropless ocular therapy for cataract surgery [3]. - PRF Technologies has established a presence in the renewable energy sector with DeepSolar, an AI-driven analytics platform for solar assets, which is moving into early commercial deployment [6]. Clinical and Preclinical Studies - In a phase 1 study, no treatment-emergent adverse events related to the study drug were observed, and no serious adverse events were reported [4]. - Preclinical rabbit studies showed favorable local tolerability for OcuRing-K, with no evidence of ocular tissue abnormalities [5]. Stock Performance - PRFX stock is currently trading 21.12% above its 20-day simple moving average (SMA) and 12.9% above its 100-day SMA, indicating short-term strength [7]. - Over the past 12 months, shares have decreased by 60.93% and are closer to their 52-week lows than highs [7]. - The stock is up 47.72% at $1.22 at the time of publication [12]. Technical Indicators - The RSI is at 47.81, indicating neutral territory, while the MACD is above its signal line, suggesting bullish momentum [7][8]. - Benzinga Edge scorecard indicates a "High-Flyer" setup with a momentum score of 83, but a low value score of 4 warns that the stock is priced for perfection [9][11].

Core Insights - PainReform Ltd. announced a name change and is expanding into diversified healthcare and AI-driven energy platforms, resulting in a 27.4% increase in share price to $1.02 in pre-market trading [1] Gainers - Acco Group Holdings Limited saw a significant gain of 219.4%, reaching $9.40 in pre-market trading [4] - Venus Concept Inc. increased by 72.2% to $2.48 [4] - Jaguar Health, Inc. rose 41.3% to $1.08 following a licensing agreement with Woodward Specialty [4] - ImmunityBio, Inc. gained 22.8% to $4.85, with preliminary net product revenue for Anktiva projected at approximately $113 million for fiscal 2025, marking a 700% year-over-year increase [4] - OneMedNet Corporation rose 14.2% to $0.9711 after a previous decline [4] - Brand Engagement Network, Inc. increased by 13.8% to $6.50 [4] - Springview Holdings Ltd rose 13.4% to $19.75 after a substantial 657% increase on Thursday [4] - Creative Global Technology Holdings Limited gained 10.7% to $4.22 after a 52% jump on Thursday [4] - Kopin Corporation increased by 8.1% to $3.20 [4] Losers - Callan JMB Inc. fell 20.7% to $3.33 after a 275% increase on Thursday due to a strategic agreement with Biostax Corp [4] - Erayak Power Solution Group Inc. decreased by 18.3% to $3.21 after an 18% rise on Thursday [4] - TryHard Holdings Limited dropped 16.4% to $6.35 following a 76% decline on Thursday due to a joint venture announcement [4] - iOThree Limited shares dipped 15% to $2.56 [4] - NOVONIX Limited fell 14% to $1.17 [4] - Moolec Science SA tumbled 13.1% to $6.69 after an 118% increase on Thursday [4] - High Roller Technologies, Inc. declined 12.9% to $20.64 after a 25% rise on Thursday [4] - Bonk, Inc. fell 10.4% to $3.55 after a 42% increase on Thursday due to acquisition news [4] - J B Hunt Transport Services Inc fell 4.2% to $197.86, reporting mixed financial results for the fourth quarter [4] - QXO Inc dipped 3.5% to $24.14 after announcing a $750 million stock offering and preliminary fourth-quarter net sales of $2.19 billion [4]

Core Viewpoint - PRF Technologies Ltd. has undergone a corporate name change from PainReform to reflect its evolution into a diversified innovation platform, expanding beyond its original single-product focus into specialty pharmaceuticals, advanced drug-delivery technologies, and AI-driven renewable-energy analytics [1][2]. Company Evolution - The name change signifies a strategic shift as the company broadens its portfolio across multiple high-growth markets, continuing to advance its non-opioid postoperative pain therapy PRF-110 while establishing additional growth platforms through LayerBio and DeepSolar [3][4]. Pharmaceutical Platform Expansion - PRF has entered the ophthalmology market with OcuRing™-K, a patented sustained-release ocular therapy aimed at addressing pain and inflammation post-cataract surgery, a multi-billion-dollar global market [4][5]. - OcuRing™-K is designed for controlled, localized therapy from a single application, eliminating the need for weeks of post-surgical eye drops, and is advancing toward the next stage of clinical development [5]. AI-Driven Energy Analytics - The company has developed DeepSolar, an AI-driven solar analytics and digital asset-management business targeting the expanding global renewable-energy market, transforming complex data into actionable intelligence for solar assets [6]. - DeepSolar has moved from development to early commercial deployment, with pilot projects progressing into customer engagements as solar assets age [6]. Strategic Growth Positioning - The transition to PRF Technologies Ltd. aims to build long-term value through diversification, platform scalability, and disciplined execution across healthcare and clean-energy technology markets [7]. - The company is focused on creating multiple platforms and paths forward, reducing reliance on any single outcome to establish durable, long-term value [8]. Company Overview - PRF Technologies Ltd. is a diversified innovation company advancing specialty pharmaceutical therapies and AI-driven energy analytics, focusing on improving patient outcomes while reducing reliance on opioids [9].

Core Insights - PainReform Ltd. has announced positive safety data from Phase I human studies and preclinical evaluations of its OcuRing™-K platform, which supports its advancement toward Investigational New Drug (IND) submission [1][6] Group 1: Safety and Efficacy - The development program included preclinical rabbit studies and a Phase I clinical study in patients undergoing cataract surgery, demonstrating a favorable safety profile for the OcuRing™-K platform [2] - In the Phase I clinical study, no treatment-emergent adverse events related to the study drug were observed, and all reported adverse events were consistent with cataract surgery expectations [3] - Preclinical studies showed favorable local tolerability with no ocular tissue abnormalities, supporting consistent safety findings across both preclinical and clinical evaluations [4] Group 2: Product Features and Development - OcuRing™-K is designed for targeted, sustained release of non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids through a single intraoperative application, utilizing a preservative-free formulation [5] - The company is advancing IND-enabling activities, with preparations underway to support the next phase of clinical evaluation in the United States [6] Group 3: Company Overview - PainReform Ltd. focuses on reformulating established therapeutics for post-operative pain management and aims to improve patient outcomes while reducing reliance on opioids [7]

Core Insights - PainReform Ltd. has launched Smart TDD, an advanced solar Technical Due Diligence service aimed at providing comprehensive assessments of solar asset performance and risk, enhancing audit capabilities for various stakeholders in the solar industry [1][4] Industry Overview - The solar industry is experiencing unprecedented growth, with over $500 billion invested in 2024 and more than $60 billion in solar assets changing hands annually, creating a significant demand for reliable technical assessments as many assets reach warranty expiration or show underperformance [2][4] Company Developments - Smart TDD addresses the limitations of traditional TDD processes by offering complete data coverage, advanced diagnostics, actionable outputs, and fast turnaround times, thus supporting all major checkpoints in a solar plant's lifecycle [3][7] - The launch of Smart TDD positions DeepSolar as a trusted analytics partner in the global solar sector, responding to the increasing demand for high-quality technical due diligence services amid rising performance issues and M&A activity [4][7] Technological Advancements - Smart TDD combines AI-driven analytics with physics-based modeling and expert engineering reviews to provide a full-picture audit, enabling investors and owners to better understand the assets they are acquiring, operating, or insuring [3][7] - The service promises to deliver preliminary results within days of data upload, significantly reducing deal friction and enhancing decision-making for buyers and financiers [7]

Core Insights - PainReform Ltd. has completed an R&D assessment of LayerBio's drop-less, sustained-release ocular drug-delivery platform, confirming its potential to reduce or eliminate reliance on medicated eye drops for cataract patients [1][4] - The platform has successfully incorporated corticosteroids and NSAIDs, indicating its technical feasibility for multi-drug delivery [2] - The OcuRing, a pre-fabricated device, allows for sustained-release drug delivery during cataract surgery, improving patient comfort and compliance, particularly among elderly patients [3] Company Overview - PainReform Ltd. focuses on reformulating established therapeutics and developing AI-driven energy optimization technologies through its DeepSolar platform, reflecting a strategic commitment to healthcare and sustainable energy [5] - The company's pharmaceutical programs utilize a proprietary extended-release drug-delivery system aimed at providing prolonged post-surgical pain relief while minimizing the need for repeated dosing and reducing reliance on opioids [5]

Core Viewpoint - PainReform Ltd. has initiated a development plan for OcuRing™-K, a patented sustained-release ocular therapy aimed at improving postoperative care in cataract surgery, targeting a significant market opportunity in the multi-billion-dollar global cataract surgery market [1][5]. Company Overview - PainReform Ltd. focuses on reformulating established therapeutics and developing AI-driven energy optimization technologies through its DeepSolar platform, reflecting a strategic commitment to applying precision technology across healthcare and sustainable energy sectors [10]. Product Development - OcuRing-K is designed as an erodible, intraoperatively administered device that provides sustained-release of ketorolac, addressing the limitations of traditional eye-drop regimens that often deliver less than 5% of the drug to the target site [2][3]. - The development plan for OcuRing-K includes progressing towards a Phase II clinical trial, with a focus on post-cataract pain and inflammation as the initial target indication [1][7]. Clinical and Market Context - Cataract surgery is a prevalent procedure, with approximately 4.5 million surgeries performed annually in the U.S. and a global surgical procedure volume exceeding $9 billion [5]. - Current postoperative management relies heavily on multi-week corticosteroid and NSAID eye-drop regimens, which are burdensome for elderly patients and often inconsistently delivered [5]. Technological Advantages - OcuRing-K's in-situ depot formulation allows for direct, localized delivery to target tissues, providing controlled and stable therapeutic coverage while reducing systemic exposure and contamination risks associated with traditional drops [3][4]. - Preclinical studies and Phase I evaluations have shown that OcuRing-K can reduce post-surgical pain and inflammation with lower total drug exposure compared to standard regimens, enhancing patient compliance [4]. Future Plans - PainReform and LayerBio plan to advance OcuRing-K through its next stage of clinical development in the U.S., which could unlock a high-volume reimbursable market and enable expansion into additional ophthalmic indications [7].

Core Insights - PainReform Ltd. has announced advancements in its solar energy business unit, DeepSolar, focusing on the development of an automated reporting engine that enhances solar asset performance analysis and communication [1][3]. Company Overview - PainReform Ltd. operates in two main sectors: reformulating established therapeutics and developing AI-driven energy optimization technologies through its DeepSolar platform [5]. - DeepSolar specializes in advanced digital asset management technologies for utility-scale solar plants, utilizing AI algorithms to convert complex operational data into actionable insights [4][5]. Product Development - The new AI-powered reporting engine aims to automate the process of generating performance reports, which currently requires manual data aggregation from various systems [2][3]. - This engine will consolidate and interpret data from multiple sources, providing customized reports in minutes, tailored to user-defined analysis depth, visualization style, and reporting frequency [3]. Strategic Vision - The automated reporting system is seen as a significant step towards making DeepSolar's AI capabilities more practical and accessible, facilitating a quicker transition from analysis to actionable insights [4].

Core Insights - PainReform Ltd.'s solar energy business unit, DeepSolar, is gaining attention for its AI-driven solar analytics, particularly through its participation in the NVIDIA Connect program [1][2] - DeepSolar Predict, an AI-based forecasting module, aims to enhance energy production forecasts and operational decision-making for solar asset managers [2][4] - The increasing operational complexity in utility-scale solar necessitates advanced data interpretation and management strategies to maintain profitability in a volatile market [3] Company Overview - DeepSolar develops advanced digital asset management technologies specifically for utility-scale solar plants, utilizing AI algorithms to transform operational data into actionable insights [6] - The company is focused on commercial deployment and is progressing towards its first pilot projects with prospective customers, indicating potential long-term value creation [5][6] - PainReform Ltd. operates with a dual business model, combining pharmaceutical programs with AI-driven energy optimization technologies through DeepSolar, reflecting a strategic commitment to high-impact sectors [7]